Department of Biomedical Sciences, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, 632014, India.
Jubilee Centre for Medical Research, Jubilee Mission Medical College and Research Institute, Thrissur, Kerala, India.
Med Oncol. 2023 Oct 7;40(11):323. doi: 10.1007/s12032-023-02168-6.
Cancer is a major threat to human life around the globe, and the discovery of novel biomolecules continue to be an urgent therapeutic need that is still unmet. Precision medicine relies on targeted therapeutic strategies. Researchers are better equipped to develop therapies that target proteins as they understand more about the genetic alterations and molecules that cause progression of cancer. There has been a recent diversification of the sorts of targets exploited in treatment. Therapeutic antibody and biotechnology advancements enabled curative treatments to reach previously inaccessible sites. New treatment strategies have been initiated for several undruggable targets. The application of tailored therapy has been proven to have efficient results in controlling cancer progression. Novel biomolecules like SMDCs, ADCs, mABs, and PROTACS has gained vast attention in the recent years. Several studies have shown that using these novel technology helps in reducing the drug dosage as well as to overcome drug resistance in different cancer types. Therefore, it is crucial to fully untangle the mechanism and collect evidence to understand the significance of these novel drug targets and strategies. This review article will be discussing the importance and role of these novel biomolecules in targeted cancer therapies.
癌症是全球范围内人类生命的主要威胁，发现新的生物分子仍然是一个未满足的迫切治疗需求。精准医学依赖于靶向治疗策略。研究人员能够更好地开发针对蛋白质的疗法，因为他们更了解导致癌症进展的遗传改变和分子。最近，治疗靶点的种类也有所多样化。治疗性抗体和生物技术的进步使以前无法到达的部位能够得到治愈性治疗。针对几个不可用药的靶点已经启动了新的治疗策略。定制疗法的应用已被证明在控制癌症进展方面具有高效的效果。近年来，像 SMDCs、ADC、mAB 和 PROTACS 等新型生物分子受到了广泛关注。多项研究表明，使用这些新技术有助于减少药物剂量，并克服不同癌症类型的耐药性。因此，充分阐明这些新型药物靶点和策略的机制并收集证据非常重要。本文将讨论这些新型生物分子在靶向癌症治疗中的重要性和作用。
